Since butyrate and other SCFAs have been reported to increase insulin sensitivity and glucagon-like-peptide-1 (GLP1) release in animal studies, reduced SCFA levels in pregnant women, and especially pregnant women with obesity, may be contributing factors for the insulin resistance commonly observed during pregnancy (37, 38). Here, INS is linked to obesity disorder.